drug

Pharmaceutical company BioPharma Services has received a $20m contract to conduct in vivo studies of generic drug products in human beings.

The five-year contract has been awarded by the US Food and Drug Administration (FDA) division Centre for Drug Evaluation and Research (CDER).

The in vivo studies are scheduled to begin later this year and expected to be completed by 2021.

BioPharma Services chief executive officer Renzo DiCarlo said: "We are very proud to work with the FDA in support of their generic drug programmes.

"This award is a great example of BioPharma’s capabilities as a leading industry expert in bioequivalence and early stage clinical research."

"This award is a great example of BioPharma’s capabilities as a leading industry expert in bioequivalence and early stage clinical research."

Through the FDA studies conducted by BioPharma, CDER will be able to answer scientific questions in developing generic approval standards, as well as ensure post-market safety and efficacy of approved generic drug products.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The studies will also help enhance the generic review practice within CDER.

BioPharma Services chief operating officer Brent Matthews said: "I am certain that our outstanding regulatory history with the FDA and our team’s extensive expertise in the conduct of Bioequivalence trials played a major role in landing this important contract with the FDA."

Under the deal, the pharmaceutical company will provide the FDA with a full service offering from study design inception to clinical conduct, bioanalysis and final report.


Image: BioPharma bags FDA contract to conduct in vivo studies of generic drug products in human beings. Photo: courtesy of Elza Fiúza / ABr – Agência Brasil.